Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 12/20 | 0.55 |
| ▸ | NPC1 | O15118 | 11/20 | 0.55 |
| ▸ | RAB9A | P51151 | 11/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493299 | 0.85 | RAB9A (0.54) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL1493423 | 0.84 | NPC1 (0.52) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL1493264 | 0.79 | CHEK1 (0.43) | LRRK2 | |
| SCHEMBL1493300 | 0.78 | CYP2A6 (0.50) | SMN1; SMN2NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL1493260 | 0.77 | FYN (0.44) | SMN1; SMN2NPC1RAB9AKDM4ENPSR1 | |
| SCHEMBL1493314 | 0.76 | MAPT (0.63) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL1666734 | 0.76 | NPC1 (0.48) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL10366374 | 0.75 | NPC1 (0.48) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL9975888 | 0.75 | NPC1 (0.48) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL5057080 | 0.75 | NPC1 (0.60) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | SMN1; SMN2 1935/4885NPC1 2144/4885RAB9A 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.